Company news
Xeris Biopharma Holdings, Inc. news in 2020
Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2020, newest first.
Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority
December 21, 2020
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
December 10, 2020
Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 8, 2020
Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
November 1, 2020
Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection
October 19, 2020
Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 7, 2020
Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer
August 19, 2020
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 9, 2020
Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
August 2, 2020
Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward
July 29, 2020
Xeris Pharmaceuticals Announces Full Exercise of Underwriters’ Options to Purchase Additional Shares and Additional Notes
July 14, 2020
Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available
June 30, 2020
Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025
June 24, 2020
Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes
June 23, 2020
Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus
June 17, 2020
Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise
June 14, 2020
Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
May 21, 2020
Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis
May 13, 2020
Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates
May 6, 2020
Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
April 29, 2020
Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020
April 28, 2020
Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection
April 19, 2020
Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes
March 25, 2020
Xeris Pharmaceuticals Reinforces the Importance of GVOKE™ PFS for People With Diabetes
March 18, 2020
Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress
March 10, 2020
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
February 26, 2020
Xeris Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares
February 19, 2020
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
February 17, 2020
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
February 10, 2020
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
February 9, 2020
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
January 5, 2020